24-hour rhythms in oxidative stress during hepatocarcinogenesis in rats: Effect of melatonin or α-ketoglutarate

Redox Report

Volumn 13, Issue 2, 2008, Pages 78-86

  Subramanian, Perumal ^a   Dakshayani, Kadiyala Babu ^a   Pandi Perumal, Seithikurippu R ^b   Trakht, Ilya ^b   Cardinali, Daniel P ^c  

^a ANNAMALAI UNIVERSITY   (India)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

ketoglutarate; Antioxidant status; Circadian rhythms; Hepatocarcinogenesis; Melatonin; N nitrosodiethylamine

Indexed keywords

2 OXOGLUTARIC ACID; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; CATALASE; DIETHYLNITROSAMINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; MELATONIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ALPHA-KETOGLUTARIC ACID; ANTIOXIDANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; ERYTHROCYTE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; WISTAR RAT;

RATTUS;

ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANIMALS; ANTIOXIDANTS; ASPARTATE AMINOTRANSFERASES; CARCINOMA, HEPATOCELLULAR; CATALASE; CIRCADIAN RHYTHM; DIETHYLNITROSAMINE; ERYTHROCYTES; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; KETOGLUTARIC ACIDS; LIPID PEROXIDATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MELATONIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 41949100581     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100008X259178     Document Type: Article

References (43)

1. IARC. N-nitrosodiethanolamine. IARC Monogr Eval Carcinog Risks Hum 2000; 77: 403-438.
2. Loeppky RN. The mechanism of bioactivation of N-nitrosodiethanolamine. Drug Metab Rev 1999; 31: 175-193.
3. Dakshayani KB, Subramanian P, Manivasagam T, Mohamed EM. Metabolic normalization of alpha-ketoglutarate against N-nitrosodiethylamine-induced hepatocarcinogenesis in rats. Fundam Clin Pharmacol 2006; 20: 477-480.
4. Subramanian P, Mirunalini S, Dakshayani K, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res 2007; 43: 305-312.
5. Levi F, Schibler U. Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007; 47: 593-628.
6. Fu L, Lee CC. The circadian clock: Pacemaker and tumour suppressor. Nat Rev Cancer 2003; 3: 350-361.
7. Dakshayami KB, Subramanian P. Alpha-ketoglutarate modulates the circadian patterns of lipid peroxidation and antioxidant status during N-nitrosodiethylamine-induced hepatocarcinogenesis in rats. J Med Food 2006; 9: 90-97.
8. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9: 25-39.
9. Cardinali DP, Furio AM, Reyes MP, Brusco U. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control 2006; 17: 601-609.
10. Muzio G, Marengo B, Salvo R, Semeraro A, Canuto RA, Tessitore L. Liver cancer is induced by a subnecrogenic dose of DENA when associated with fasting/refeeding: Role of glutathione-transferase and lipid peroxidation. Free Radic Biol Med 1999; 26: 1314-1320
11. Sundaresan S, Subramanian P. S-Allylcysteine inhibits circulatory lipid peroxidation and promotes antioxidants in N-nitrosodiethylamine-induced carcinogenesis. Pol J Pharmacol 2003; 55: 37-42.
12. Dakshayani KB, Subramanian P, Manivasagam T, Essa MM, Manoharan S. Melatonin modulates the oxidant-antioxidant imbalance during N-nitrosodiethylamine induced hepatocarcinogenesis in rats. J Pharm Pharm Sci 2005; 8: 316-321.
13. Velvizhi S, Dakshayani KB, Subramanian P. Protective influences of alpha-ketoglutarate on lipid peroxidation and antioxidant status in ammonium acetate treated rats. Indian J Exp Biol 2002; 40: 1183-1186.
14. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.
15. Niehaus Jr WG, Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968; 6: 126-130.
16. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys 1959; 82: 70-79.
17. Kakkar P, Das B, Viswanathan A. A modified spectrophotometric assay of superoxide dismutase. Ind J Biochem Biophys 1984; 21: 130-132.
18. Sinha KA. Colorimetric assay of catalase. Anal Biochem 1972; 47: 3889-3894.
19. Rotruck JT, Pope AL, Gauther HE, Swanson AB, Hafeman DG, Hoekstna WG. Selenium: Biochemical roles as component of glutathione peroxidase. Science 1973; 179: 588-590.
20. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
21. Nelson, TV, Tong YL, Lee JK, Halberg F. Methods for cosinorrhythmometry. Chronobiologia 1979; 6: 305-323.
22. Archer MC. Mechanisms of action of N-nitroso compounds. Cancer Surv 1989; 8: 241-250.
23. Ozben T. Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci 2007; 96: 2181-2196.
24. Flora SJ. Role of free radicals and antioxidants in health and disease. Cell Mol Biol (Noisy-le-grand) 2007; 53: 1-2.
25. Higst DG, Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007; 12: 3406-3418.
26. Serafini M, Villano D, Spera G, Pellegrini N. Redox molecules and cancer prevention: The importance of understanding the role of the antioxidant network. Nutr Cancer 2006; 56: 232-240.
27. Otteneder MB, Knutson CG, Daniels JS et al. In vivo oxidative metabolism of a major peroxidation-derived DNA adduct, M1dG. Proc Natl Acad Sci USA 2006; 103: 6665-6669.
28. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: New findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54: 1-9.
29. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
30. Osseni RA, Rat P, Bogdan A, Warnet JM, Touitou Y. Evidence of prooxidant and antioxidant action of melatonin on human liver cell line HepG2. Life Sci 2000; 68: 387-399.
31. Wolfter A, Caluba HC, Abuja PM, Dobr G, Schauenstein K, Liebmann PM. Prooxidant activity of melatonin promotes fas-induced cell death in human leukemic Jurkat cells. FEBS Lett 2001; 502: 127-131.
32. Sakano K, Oikawa S, Hiraku Y, Kawanishi S. Oxidative DNA damage induced by a melatonin metabolite, 6-hydroxymelatonin, via a unique non-o-quinone type of redox cycle. Biochem Pharmacol 2004; 68: 1869-1878.
33. Imaida K, Hagiwara A, Yoshino H et al. Inhibitory effects of low doses of melatonin on induction of preneoplastic liver lesions in a medium-term liver bioassay in F344 rats: Relation to the influence of electromagnetic near field exposure. Cancer Lett 2000; 155: 105-114.
34. van den HS, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, Levi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci 1999; 64: 2523-2534.
35. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol 2001; 2: 307-315.
36. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000; 92: 994-1000.
37. Wirz-Justice A, Krauchi K, Cajochen C, Danilenko KV, Renz C, Weber JM. Evening melatonin and bright light administration induce additive phase shifts in dim light melatonin onset. J Pineal Res 2004; 36: 192-194.
38. Moser M, Schaumberger K, Schernhammer E, Stevens RG. Cancer and rhythm. Cancer Causes Control 2006; 17: 483-487.
39. Filipski E, Li XM, Levi F. Disruption of circadian coordination and malignant growth. Cancer Causes Control 2006; 17: 509-514.
40. Iee CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control 2006; 17: 525-530.
41. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006; 1757; 573-589
42. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: The neuroendocrine/circadian melatonin signal. Endocrine 2005; 27: 179-188.
43. Subramanian P, Mirunalini S, Pandi-Perumal SR, Trakht I, Cardinali DP. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol 2007; 571: 116-119.